TRN 003
Alternative Names: TRN - 003Latest Information Update: 15 Feb 2023
At a glance
- Originator Turn Biotechnologies
- Class Stem cell therapies
- Mechanism of Action Cell replacements; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Glaucoma
- Discontinued Cartilage disorders; Osteoarthritis
Most Recent Events
- 15 Feb 2023 Preclinical trials in Glaucoma in USA (unspecified route) (Turn Biotechnologies pipeline, February 2023)
- 08 Feb 2023 Discontinued - Preclinical for Cartilage disorders in USA (unspecified route) (Turn Biotechnologies pipeline, February 2023)
- 08 Feb 2023 Discontinued - Preclinical for Osteoarthritis in USA (unspecified route) (Turn Biotechnologies pipeline, February 2023)